B. Riley lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $14 from $17 and keeps a Neutral rating on the shares following the Q1 report. The firm says the company faces significant competition from Padcev -plus pembro in bladder cancer, and a shift toward novel pipeline programs appears unlikely based on current activity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCYC:
- Bicycle Therapeutics price target lowered to $22 from $26 at Citizens JMP
- Bicycle Therapeutics Reports Q1 2025 Progress and Financials
- Bicycle Therapeutics price target lowered to $15 from $40 at Barclays
- Bicycle Therapeutics: Promising Advancements and Strong Financial Position Justify Buy Rating
- Promising Developments in Bicycle Therapeutics’ Pipeline Bolster Buy Rating